From The Editor | September 22, 2026

Root Causes, Part 3: The Hidden Cost of Clinical Supply Work That Doesn't Move Trials Forward

Rgrabenhofer headshot

By Rachel Grabenhofer, Chief Editor, Clinical Supply Leader

businesswoman hiding behind stack folders-GettyImages-915451280
Behind every amendment, delay, or correction is time spent reconciling information that was never fully aligned.

How Upstream Decisions Shape Clinical Supply Outcomes: A Five-Part Video Series

In the third installment of our Root Causes series, Elena (Ella) Sinclair and Tatyana Matveeva, Ph.D., examine the work that consumes significant time and resources across clinical development, operations, and supply teams. From document reconciliation and cross-functional reviews to forecasting and planning assumptions, they discuss where organizations may be investing effort without necessarily improving execution.

(Revisit part 1 and part 2 here)

Main Highlights

  • Why teams spend so much time reconciling protocols, schedules, budgets, and vendor documentation
  • The operational burden of maintaining multiple sources of truth
  • How manual review processes contribute to delays, burnout, and amendments
  • Why highly skilled personnel are often pulled away from higher-value work
  • The hidden costs of administrative complexity
  • How forecasting models can create false confidence when underlying assumptions remain unchanged
  • Why enrollment projections and site assumptions must be continuously re-evaluated
  • The difference between managing uncertainty and pretending it doesn't exist
  • How administrative complexity consumes resources that could otherwise be used to identify and mitigate supply risk
  • Why maintaining multiple sources of truth increases the likelihood of amendments and downstream supply disruptions

Watch now:

About the Experts

Elena (Ella) Sinclair is a principal consultant at FlexPoint Bio, focused on operational strategy and logistics, clinical vendor outsourcing, and clinical quality assurance. She’s held various leadership roles, including as CEO and co-founder of the Life Science & Tech Consultants Association, and as both Seattle Chapter Chair of the membership committee and board member for the Women in Bio organization. She also served in clinical trial and operations management and director roles for five years at Sangamo Therapeutics – after 17+ years in clinical research at UT Southwestern Medical Center.

Tatyana Matveeva, Ph.D., is a neuroscientist with a background in systems and molecular neuroscience. She is now director of cGMP operations for cell therapy and regenerative medicine at a major university and connected hospital. There, she helped build a GMP cell therapy facility from the ground up — creating the full GMP infrastructure, programs, documentation, and training required to support early phase clinical trials.

What’s Next – Root Causes, Part 4: Why Clinical Supply Teams Are Always Firefighting

Even well-planned studies can become reactive once enrollment begins. Part 4 explores what happens when static plans encounter dynamic reality and why firefighting persists across clinical trial execution.

Follow Clinical Supply Leader and subscribe to our newsletter for future installments in the Root Causes series.